Affinivax Reacquires Rights from Astellas for ASP3772, a Novel 24-valent Streptococcus pneumoniae Vaccine Candidate from Affinivax’s MAPS™ Platform
CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Affinivax, Inc. (“Affinivax”) and Astellas Pharma Inc. (“Astellas”) today announced that…